opko.com
Strategic Investments Overview - OPKO
http://www.opko.com/strategic-investments
OPKO Mexico Privacy Policy / Aviso de Privacidad. OPKO’s growth strategy includes investing in early-stage companies that we perceive to have valuable proprietary technology and significant potential to create value for OPKO as a shareholder. Some of our investments include:. MABVAX (San Diego, CA) Mabvax Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative vaccine and monoclonal antibody-based therapeutics for the diagnosis and treatment of cancer&#...
opko.com
2013 Forms 8937 - OPKO
http://www.opko.com/investor-relations/2013-forms-8937
OPKO Mexico Privacy Policy / Aviso de Privacidad. January 15, 2014. Re: Notification of changes to stockholder basis. In connection with OPKO Health, Inc.’s board of directors declaring a dividend on the Series D Preferred Stock that you hold, as well as. 8216;s stock for stock acquisition of PROLOR Biotech Inc. We are required to furnish copies of the Forms 8937 we filed with the IRS to the affected shareholders. 2014 OPKO Health Inc.
opko.com
Asthma and COPD - OPKO
http://www.opko.com/therapeutics/asthma-copd
OPKO Mexico Privacy Policy / Aviso de Privacidad. OPKO owns global rights to a heparin-derived oligosaccharide intended for therapeutic use in asthma and COPD (chronic obstructive pulmonary disease). It is expected to demonstrate decreased side effects and improved efficacy as compared to current medications. 2014 OPKO Health Inc.
opko.com
OPKO Europe - OPKO
http://www.opko.com/products/opko-europe
OPKO Mexico Privacy Policy / Aviso de Privacidad. OPKO Mexico Privacy Policy / Aviso de Privacidad. Is a Barcelona-based company engaged in the development, manufacturing, marketing, and sale of a robust line of pharmaceutical, nutraceutical, and veterinary products in Europe. OPKO EU possesses an experienced management team and a strong product development pipeline. We believe that it is positioned to address significant market opportunities in both Europe and Latin America. 2014 OPKO Health Inc.
opko.com
OPKO-CURNA - OPKO
http://www.opko.com/therapeutics/opko-curna
OPKO Mexico Privacy Policy / Aviso de Privacidad. Learn More About OPKO's Protein Up-Regulation Platform. OPKO-CURNA is developing a unique therapeutic modality focusing on the targeted up-regulation of protein levels via the targeted up-regulation of gene expression. In contrast to RNA interference or gene therapy, our CURNA platform utilizes antagoNATs: chemically-modified, single-stranded oligonucleotides that interfere with the function of natural antisense transcripts (NATs). OPKO believes that anta...
opko.com
Therapeutics Overview - OPKO
http://www.opko.com/therapeutics/overview
OPKO Mexico Privacy Policy / Aviso de Privacidad. Vitamin D and Phosphate Management Products. OPKO announced on March 4, 2013 that it had acquired all of the assets of Cytochroma, Inc. Which form the core of the OPKO Health Renal Division. Cytochroma’s products, currently in Phase 3 clinical development, include a vitamin D compound, Rayaldee , and a phosphate binder, Alpharen , for use in chronic kidney disease patients. Growth Hormone, Hemophilia and Obesity Products. 2014 OPKO Health Inc.
opko.com
Rolapitant - OPKO
http://www.opko.com/therapeutics/cinv-and-ponv
OPKO Mexico Privacy Policy / Aviso de Privacidad. Rolapitant is potentially a best-in-class supportive care product for Chemotherapy-induced nausea and vomiting (CINV). Characteristics include:. Long-acting (5 day activity as opposed to 1 or 2 days for other treatments). In October 2009, OPKO acquired Rolapitant. A potent and selective competitive antagonist of the NK-1 receptor, in addition to other neurokinin-1 (NK-1) assets from Schering Plough Corporation. License Agreement with TESARO.
opko.com
OPKO FineTech - OPKO
http://www.opko.com/products/opko-finetech
OPKO Mexico Privacy Policy / Aviso de Privacidad. OPKO Mexico Privacy Policy / Aviso de Privacidad. Learn More About FineTech's Product Pipeline. Is a profitable Israeli company engaged in the development and production of high-value, high-potency specialty APIs (active pharmaceutical ingredients). FineTech’s fully developed commercial APIs include:. FineTech’s facility is equipped to perform a variety of scientific functions, including:. Impurity identification and analytical markers certification.
opko.com
Protein-Based Vaccines - OPKO
http://www.opko.com/therapeutics/protein-based-vaccines
OPKO Mexico Privacy Policy / Aviso de Privacidad. Learn More About Academia Sinica. OPKO has acquired rights from Taiwan’s Academia Sinica to a new technology for the development of protein-based vaccines against influenza and other viral infections. The vaccine is expected to provide protection from multiple influenza strains, ranging from seasonal influenza to global pandemics such as swine and avian flu. 2014 OPKO Health Inc.
